Skip to content
February 04, 2023

Equity.Guru

Investment information for the new generation

Gauntlet with Chris Parry

Critical minerals are taking focus as we push ahead to the green energy economy. With the majority of critical minerals and rare earth elements being imported from less-than friendly…
Specialty pharma companies, like Medexus Pharmaceuticals (MDP.T), have an advantage over tradition pharmaceutical drug developers as they provide pre-approved products and typically don’t need to go through the FDA…
Chris Parry, Equity.Guru founder, speaks with Keith Driver, CEO & director of Replenish Nutrients (ERTH.C), a Canadian-based developer of leading-edge regenerative fertilizers, and asks how the company’s narrowing of…
Chris Parry, Equity.Guru founder, sits down with Ian Atkinson, president and CEO of Southern Energy (SOU.V) and asks why we still need gas in the 21st century green economy…
In today’s episode, Equity.Guru founder, Chris Parry, talks with Ken d’Entremont, CEO and director of Medexus Pharmaceuticals, and asks about the company’s recent strong financials, the possible inclusion of…
Today, Chris Parry, founder of Equity.Guru, speaks with NioCorp (NB.T) CEO, president and executive chairman, Mark Smith and company COO, Mark Honan, regarding the company’s flagship Elk Creek critical…
Today, Equity.Guru founder, Chris Parry, sits down with Gabriel Rene, founder and CEO of Verses Technologies (VERS.NEO) and asks how Verses stands to create a whole new world of…
Karim Rayani, CEO of Falcon Gold (FG.V), speaks with Chris Parry, Equity.Guru founder, to explain how the company’s portfolio acquisition strategy portends a greater value than what the market…
Alex Klenman, president, CEO & director of Azincourt Energy (AAZ.V), sits down with Chris Parry, founder of Equity.Guru, to address investor concerns over the company’s latest press release announcing…
Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO), a Canadian-based psychedelics company focused on the natural extraction and clinical delivery of psilocybin compounds, faces off with Equity.Guru…